<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01558921</url>
  </required_header>
  <id_info>
    <org_study_id>NL36315.042.11</org_study_id>
    <secondary_id>2010-023957-12</secondary_id>
    <nct_id>NCT01558921</nct_id>
  </id_info>
  <brief_title>Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial</brief_title>
  <acronym>RAPIDO</acronym>
  <official_title>Randomized Multicentre Phase III Study of Short Course Radiation Therapy Followed by Prolonged Pre-operative Chemotherapy and Surgery in Primary High Risk Rectal Cancer Compared to Standard Chemoradiotherapy and Surgery and Optional Adjuvant Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently the 3-year disease free survival of patients with locally advanced rectal cancer is
      about 50%. Current standard treatment for patients at high risk of failing locally and/or
      systemically includes pre-operative long course radiotherapy (5 weeks) in combination with
      chemotherapy (so called neoadjuvant chemoradiotherapy). The neoadjuvant chemoradiotherapy has
      been demonstrated to improve local control, but had no effect on the overall survival.
      Different studies in patients with rectal cancer studying the effect of adjuvant post
      operative chemotherapy did not result in an improved survival. This may be due the fact that
      rectal cancer surgery (TME) is associated with a high complication rate so substantial
      proportion of patients cannot receive chemotherapy postoperatively. An alternative approach
      is to administer the systemic therapy preoperative. To guarantee control of the rectum tumor
      short-course radiotherapy (5 days) is given, as different studies showed local control of the
      tumor for a long time. During this waiting period the patient is in a good condition to
      receive an optimal dose of chemotherapy. The investigators hypothesize that with this
      proposed protocol both the local tumour and possible micrometastases are effectively treated
      and that this will result in an increased survival. The investigators will compare this with
      the standard treatment of neoadjuvant chemoradiation followed by TME surgery and optional
      adjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized between an experimental group (arm B) in which short course 5 x 5
      Gy radiation scheme is followed by six cycles of combination chemotherapy (capecitabine/5FU
      and oxaliplatin) and surgery and a control group (arm A) with long course chemoradiotherapy
      followed by surgery. In arm A adjuvant chemotherapy is allowed according to the local
      protocol of the institution. In both groups the rectal tumour will be removed by TME surgery
      or more extensive surgery if required because of tumour extent.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 21, 2011</start_date>
  <completion_date type="Anticipated">June 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 8, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>standard arm: 5.5 weeks chemoradiation -&gt; surgery -&gt; optional chemotherapy experimental arm: 5x5Gy -&gt; 12 wks chemotherapy -&gt; surgery</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to disease related treatment failure (TdrTF)</measure>
    <time_frame>3 year follw-up after surgery</time_frame>
    <description>TdrTF = time between randomization and either local or distant relapse or death caused by the rectal carcinoma whichever comes first. In case of nonrectal cancer related death patients will be censored at date of death. In case of a second primary tumour patients will be censored at the date of diagnosis of the second primary tumour. In case no resection or no surgery could be done or M1 at restaging or during surgery TdrTF= 0 (date of randomization). In case of local regrowth after wait &amp; watch strategy, followed by no resection or R2 resection time to date of diagnosis local regrowth is taken. Patients lost to follow-up will be censored the last date of patient visit.Survival curves for disease-free survival after 3 years of follow-up will be constructed using the method of Kaplan and Meier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 year</time_frame>
    <description>Overall survival will be computed as the time between randomization and colorectal cancer or treatment related death. Patients lost to follow-up will be censored the last date of patient visit.
In case of a second primary tumour patients will be censored at the date of diagnosis of the second primary tumour.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRM negative rate</measure>
    <time_frame>within 30 days</time_frame>
    <description>Circumferential resection margin &gt; 1 mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pCR rate</measure>
    <time_frame>within 30 days</time_frame>
    <description>Pathological complete response after neo-adjuvant treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short and long-term toxicity</measure>
    <time_frame>3 year follow-up</time_frame>
    <description>Treatment associated toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complications</measure>
    <time_frame>3 year follow-up</time_frame>
    <description>wound rupture, bleeding, infection, rectal anastomotic leak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 year after surgery</time_frame>
    <description>QLQ-C30, QLQ-CR-29+,QLQ-CIPN20, LARS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">920</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>B: 5x5Gy -&gt; CAPOX -&gt; surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>experimental group (arm B) M1 scheme</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A: 5 weeks chemoradiation -&gt; surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control group (arm A) standard long course chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>M1 scheme</intervention_name>
    <description>short course 5 x 5 Gy radiation scheme is followed by six cycles of combination chemotherapy (capecitabine and oxaliplatin (CAPOX)) and surgery. FOLFOX4 may be given as alternative for CAPOX</description>
    <arm_group_label>B: 5x5Gy -&gt; CAPOX -&gt; surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard long course chemoradiotherapy</intervention_name>
    <description>long course chemoradiotherapy followed by surgery. Optional adjuvant chemotherapy (CAPOX or FOLFOX) is allowed in the control group.</description>
    <arm_group_label>A: 5 weeks chemoradiation -&gt; surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Primary tumour characteristics:

          1. Histological proof of newly diagnosed primary adenocarcinoma of the rectum

          2. Locally advanced tumour fulfilling at least one of the following criteria on pelvic
             MRI indicating high risk of failing locally and/or systemically (T4a, i.e. overgrowth
             to an adjacent organ or structure like the prostate, urinary bladder, uterus, sacrum,
             pelvic floor or side wall (according to TNM version 5), cT4b, i.e. peritoneal
             involvement, extramural vascular invasion (EMVI+). N2, i.e. four or more lymph nodes
             in the mesorectum showing morphological signs on MRI indicating metastatic disease.
             Positive MRF, i.e. tumor or lymph node &lt; 1 mm from the mesorectal fascia. Enlarged
             lateral nodes, &gt; 1 cm (lat LN+)

        Exclusion Criteria:

          1. Extensive growth into cranial part of the sacrum (above S3) or the lumbosacral nerve
             roots indicating that surgery will never be possible even if substantial tumour
             down-sizing is seen

          2. Presence of metastatic disease or recurrent rectal tumour

          3. Familial Adenomatosis Polyposis coli (FAP), Hereditary Non-Polyposis Colorectal Cancer
             (HNPCC), active Crohn¡¦s disease or active ulcerative Colitis

          4. Concomitant malignancies, except for adequately treated basocellular carcinoma of the
             skin or in situ carcinoma of the cervix uteri. Subjects with prior malignancies must
             be disease-free for at least 5 years

          5. Known DPD deficiency

          6. Any contraindications to MRI (e.g. patients with pacemakers)

          7. Medical or psychiatric conditions that compromise the patient's ability to give
             informed consent

          8. Concurrent uncontrolled medical conditions

          9. Any investigational treatment for rectal cancer within the past month

         10. Pregnancy or breast feeding

         11. Patients with known malabsorption syndromes or a lack of physical integrity of the
             upper gastrointestinal tract

         12. Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure,
             symptomatic coronary artery disease and cardiac dysrhythmia, e.g. atrial fibrillation,
             even if controlled with medication) or myocardial infarction within the past 12 months

         13. Patients with symptoms or history of peripheral neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>B. van Etten, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen, Department of Surgery, Groningen, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>B. Glimelius, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akademiska sjukhuset, Department of Oncology, Uppsala, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. A. Hospers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University medical Center Groningen, Department of Medical Oncology, Groningen, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. Nilsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Universitetssjukhuset, Stockholm, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C. J. van de Velde, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center, Department of Surgery, Leiden, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C.A.M. Marijnen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Siteman Cancer Center, Washington University Medical School</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg Universitetshospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <state>Po Box 30001</state>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nki / Avl</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelmina Ziekenhuis</name>
      <address>
        <city>Assen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Groep</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ommelander Ziekenhuis Groep</name>
      <address>
        <city>Delfzijl</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronovo Ziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HaGaZiekenhuis</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deventer Hospital</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina ZIekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Het Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>de Tjongerschans</name>
      <address>
        <city>Heerenveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente</name>
      <address>
        <city>Hengelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnland Ziekenhuis</name>
      <address>
        <city>Leiderdorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Nijmegen St Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Sneek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sørlandet Sykehus Kristiansand</name>
      <address>
        <city>Kristiansand</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Hospital Duran I Reynals</name>
      <address>
        <city>L'HOSPITALET de LLOBREGAT</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospital General Universitario Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic la Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Södra Älvsborgs Sjukhus</name>
      <address>
        <city>Borås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mälarsjukhuset</name>
      <address>
        <city>Eskilstuna</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Falu Lasarett</name>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gävle sjukhus</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalmar Hospital</name>
      <address>
        <city>Kalmar</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralsjukhuset i Karlstad</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linköpings Universitet</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunderby sjukhus</name>
      <address>
        <city>Luleå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset i Lund</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skaraborgs Sjukhus</name>
      <address>
        <city>Skövde</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundsvalls Sjukhus</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrallasarett</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrallasarettet Växjö</name>
      <address>
        <city>Växjö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset ÖREBRO</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dccg.nl/trial/rapido</url>
    <description>Dutch Colorectal CancerGroup</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2012</study_first_submitted>
  <study_first_submitted_qc>March 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2012</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>B. van Etten, MD, PhD</investigator_full_name>
    <investigator_title>Dr. B. van Etten, surgical oncologist</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>5x5</keyword>
  <keyword>capecitbine</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>CAPOX</keyword>
  <keyword>FOLFOX</keyword>
  <keyword>folinic acid</keyword>
  <keyword>fluorouracil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

